Sample Request

Rosacea Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

SELECT LICENSE:

Published on 09/16/2020| Code: GER21100| Category: Healthcare & Life Sciences| Total Pages: 135

Credible Markets’s Pipeline Drugs Analytics Report "Rosacea Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020" provides a detailed overview on Rosacea Competitive Space. Report provides deep insights on pipeline drug’s influence on ongoing and near future market and market dynamics, drivers, restraints and unmet needs of Rosacea pipeline drugs, pipeline analytics outlook, pipeline analytics, epidemiological studies, deals analytics, patent analytics of pipeline drugs, pipeline drug descriptions and development milestones, clinical trial analytics, competitive landscape through benchmarking and opportunity assessments and emerging company profiles.
Pipeline Drug’s Influence on Ongoing and near Future Market and Market Dynamics
Credible Markets’s Pipeline Drugs Analytics Report assess the estimated market share of late clinical stage pipeline drugs post their regulatory approvals by analyzing the already approved drugs market data analytics and through epidemiological studies. Thereby report provides clear outline on how current late stage pipeline drugs can influence the near future market and market dynamics specific to Rosacea.
Drivers, Restrains, Unmet Needs and Opportunities:
Report offers and provides a deep knowledge on the drivers, restraints and unmet needs and the opportunities derived upon a far-reaching study on the market trends and underlying factors affecting Rosacea landscape.
Pipeline Analytics Outlook:
Report summarize the comparative snapshots of all pipeline drugs as per the segments like stages of development, Geography, Route of Administration, Drug Class, Mechanism of Action, molecule type, target receptors and company types.
Pipeline Analytics:
The section covers all the molecules (drug candidates) in different stages of development (Discovery, Pre-clinical, Phase 1, Phase 2, Phase 3 and Pre-registration). It also offers information about the terminated and discontinued molecules. Analytics have been provided by Geography (covers major regions like the US, EU, Asia); by Route of Administration, by Drug Class and by Mechanism of Action. Report explains pipeline analytics by molecule type, target receptor and pipeline analytics by company type. Report also covers pipeline analytics by Universities and Institutes.
Epidemiological Studies:
Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.
Deals Analytics:
The report bestows explicit information about the collaborations and partnering activities and trend in Rosacea landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.
Patent Analytics of Pipeline Drugs:
The section even contains a thorough analysis on the intellectual property pertaining to Rosacea pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.
Pipeline Drug Descriptions and Development Milestones:
Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.
Clinical Trial Analytics:
The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Rosacea Therapeutics.
Competitive Landscape and Opportunity Assessments:
The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Rosacea. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.
Emerging Company Profiles:
Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

CHAPTER 01: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. ABOUT US: Credible Markets DATA SERVICES
CHAPTER 02: EXECUTIVE SUMMARY
2.1. REPORT SUMMARY
2.2. KEY EVENTS IN THE ROSACEA COMPETITIVE SPACE
2.3. REPORT MAJOR FINDINGS
2.3.1. DRIVERS
2.3.2. RESTRAINTS
2.3.3. OPPORTUNITIES
2.4. MARKET DYNAMICS OF ROSACEA COMPETITIVE LANDSCAPE
2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY
2.4.4. NEW DRUGS PRICING AND PRICING STRATEGIES
2.4.4.1. ESTIMATED MARKET SHARE OF LATE CLINICAL STAGE PIPELINE DRUGS
2.4.4.2. INFLUENCE ON ONGOING AND NEAR FUTURE MARKET
2.4.4.3. IMPACT ON NEW DRUG DEVELOPERS AND MANUFACTURES
2.4.4.4. IMPACT ON PATIENTS
CHAPTER 03: PIPELINE ANALYTICS OUTLOOK
3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS
3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION
3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET
3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE
CHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES
4.1. DISEASE DEFINITION AND SYMPTOMS
4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY
4.3. DISEASE DIAGNOSIS
4.4. TREATMENT ALGORITHM AND GUIDELINES
4.5. EPIDEMIOLOGY STUDIES
4.5.1. GLOBAL AND HISTORICAL TRENDS
4.6. EPIDEMIOLOGY FORECAST
4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
CHAPTER 05: DEALS (M&A) ANALYTICS OF ROSACEA COMPETITIVE LANDSCAPE
5.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
5.1.1 DEALS ANALYTICS BY DEAL TYPE
5.1.1.1. COLLABORATION DEALS
5.1.1.2. LICENSING DEALS
5.1.1.3. FINANCING DEALS
5.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
5.1.3 DEALS ANALYTICS BY ACTIVE PLAYER
CHAPTER 06: PATENT ANALYTICS OF ROSACEA PIPELINE DRUGS
6.1. PATENT ANALYTICS BY GEOGRAPY
6.2. PATENT ANALYTICS BY PATENT EXPIRY
6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS
CHAPTER 07: PIPELINE DRUGS ANALYTICS OF ROSACEA
7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
7.1.1. PRE-REGISTRATION PIPELINE DRUGS
7.1.2. PHASE III PIPELINE DRUGS
7.1.3. PHASE II PIPELINE DRUGS
7.1.4. PHASE I/II PIPELINE DRUGS
7.1.5. PHASE I PIPELINE DRUGS
7.1.6. PRE-CLINICAL PIPELINE DRUGS
7.1.7. EARLY R&D PIPELINE DRUGS
7.1.8. INACTIVE AND DISCONTINOUED PIPELINE DRUGS
7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
7.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
7.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
7.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
7.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
7.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
8.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
8.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
8.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
8.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
8.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
CHAPTER 09: ESTIMATED APPROVAL TIMELINES OF ROSACEA PIPELINE DRUGS
9.1. METHODOLOGY
9.2. ESTIMATED APPROVAL TIMELINES US & EX-US
CHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING
10.1. EXTERNAL DEPENDENCIES
10.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING
10.2. PIPELINE PORTFOLIO
10.3. EXPECTED MARKET ENTRIES
10.4. PATENTS AND EXCLUSIVITY
10.5. MARKET DYNAMICS AND PARTNERING
10.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
10.7. COMPANY DEVELOPMENTS
CHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE
11.1. EMERGING COMPANIES
11.1.1 EMERGING COMPANY PROFILES

LIST OF TABLES
• TABLE 01: ROSACEA REPORT HIGHLIGHTS IN NUMERICALS
• TABLE 02: COLLABORATION DEALS IN ROSACEA THERAPEUTIC AREA
• TABLE 03: LICENSING DEALS IN ROSACEA THERAPEUTIC AREA
• TABLE 04: FINANCING DEALS IN ROSACEA THERAPEUTIC AREA
• TABLE 05: ROSACEA PHASE III PIPELINE MOLECULES
• TABLE 06: ROSACEA PHASE II PIPELINE MOLECULES
• TABLE 07: ROSACEA PHASE I/II PIPELINE MOLECULES
• TABLE 08: ROSACEA PHASE I PIPELINE MOLECULES
• TABLE 09: PRECLINICAL STAGE DRUG CANDIDATES FOR ROSACEA
• TABLE 10: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
• TABLE 11: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
• (Remaining Tables can be seen in detailed Report)

LIST OF FIGURES
• FIGURE 01: KEY EVENTS IN THE ROSACEA COMPETITIVE SPACE
• FIGURE 02: ROSACEA DEAL ANALYTICS BY DEAL TYPE
• FIGURE 03: ROSACEA DEAL ANALYTICS BY DEAL FREQUENCY
• FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
• FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
• FIGURE 06: ROSACEA DRUGS PIPELINE ANALYTICS BY ROA
• FIGURE 07: ROSACEA DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
• FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD
• FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
• FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
• FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
• FIGURE 12: ROSACEA PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
• FIGURE 13: ROSACEA PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT
• FIGURE 14: ROSACEA COMPANIES (NUMBER, PERCENT SHARE)
• FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON ROSACEA
• (Remaining Figures can be seen in detailed Report)

Our Clients

BIC
Suntory Holdings
Continental AG
Ernst Klett
felix
IF Logo
ITC logo
jc
KB
KKR
LR
LSC
Mizuno corporation
Prospect
SRG
Sumitomo
Taichin logo
The Cleanest Way
Meat & Livestock Australia Limited
LEK
IFFCO
STTS
Laundry Capital LLC
Chippenhook Corporation
SAB
IJIN
Hooton
Medica
Medalliacne
Shanghai Chenzhu Instrument Co., Ltd.
Sanofi
Kleen Linnebo und Partner GbR
Bond-Pro, Inc.
E&L Faster Food Imports Inc.
Okinawa Institute of Science and Technology

Need Help?

Please fill form below:

Contact Us

99 WALL STREET #2124 NEW YORK, NY 10005